357 related articles for article (PubMed ID: 29705819)
1. Paradoxical pustular psoriasis induced by ustekinumab in a patient with Crohn's disease-associated spondyloarthropathy.
Benzaquen M; Flachaire B; Rouby F; Berbis P; Guis S
Rheumatol Int; 2018 Jul; 38(7):1297-1299. PubMed ID: 29705819
[TBL] [Abstract][Full Text] [Related]
2. The Efficacy of Biologic Therapy for the Management of Palmoplantar Psoriasis and Palmoplantar Pustulosis: A Systematic Review.
Sanchez IM; Sorenson E; Levin E; Liao W
Dermatol Ther (Heidelb); 2017 Dec; 7(4):425-446. PubMed ID: 29143230
[TBL] [Abstract][Full Text] [Related]
3. Ustekinumab for the treatment of paradoxical skin reactions and cutaneous manifestations of inflammatory bowel diseases.
Wu J; Smogorzewski J
Dermatol Ther; 2021 May; 34(3):e14883. PubMed ID: 33594811
[TBL] [Abstract][Full Text] [Related]
4. Paradoxical Reactions: Anti-Tumor Necrosis Factor Alpha Agents, Ustekinumab, Secukinumab, Ixekizumab, and Others.
Puig L
Curr Probl Dermatol; 2018; 53():49-63. PubMed ID: 29131037
[TBL] [Abstract][Full Text] [Related]
5. Paradoxical Psoriasis Induced by Ustekinumab: A Comprehensive Review and Case Report.
Klimko A; Olteanu AO; Tieranu I; Orzan OA; Toma CV; Ionescu EM; Preda CM; Tieranu CG
Medicina (Kaunas); 2024 Jan; 60(1):. PubMed ID: 38256367
[TBL] [Abstract][Full Text] [Related]
6. Development of psoriasis scalp with alopecia during treatment of Crohn's disease with infliximab and rapid response to both diseases to ustekinumab.
Andrisani G; Marzo M; Celleno L; Guidi L; Papa A; Gasbarrini A; Armuzzi A
Eur Rev Med Pharmacol Sci; 2013 Oct; 17(20):2831-6. PubMed ID: 24174369
[TBL] [Abstract][Full Text] [Related]
7. Anti-tumour necrosis factor alpha therapy and increased risk of de novo psoriasis: is it really a paradoxical side effect?
Joyau C; Veyrac G; Dixneuf V; Jolliet P
Clin Exp Rheumatol; 2012; 30(5):700-6. PubMed ID: 22935567
[TBL] [Abstract][Full Text] [Related]
8. Adalimumab-induced scalp psoriasis with severe alopecia as a paradoxical effect in a patient with Crohn's disease successfully treated with ustekinumab.
Koumaki D; Koumaki V; Katoulis A; Lagoudaki E; Boumpoucheropoulos S; Stefanidou M; Miaris O; Baltaga L; Evangelou G; Zografaki K; Krueger-Krasagakis SE; Krasagakis K
Dermatol Ther; 2020 Jul; 33(4):e13791. PubMed ID: 32510744
[No Abstract] [Full Text] [Related]
9. A Rare Case of New-Onset Crohn's Disease in a Patient With Chronic Palmoplantar Pustulosis.
Tanida S; Yoshii S; Kubo R; Takahama T; Sasoh S; Kubota Y; Ban T; Ando T; Nakamura M; Joh T
J Clin Med Res; 2023 Apr; 15(4):243-249. PubMed ID: 37187712
[TBL] [Abstract][Full Text] [Related]
10. Paradoxical ulcerative colitis during adalimumab treatment of psoriasis resolved by switch to ustekinumab.
Kolios AGA; Biedermann L; Weber A; Navarini AA; Meier J; Cozzio A; French LE
Br J Dermatol; 2018 Feb; 178(2):551-555. PubMed ID: 28477389
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of ustekinumab against infliximab-induced psoriasis and arthritis associated with Crohn's disease.
Matsumoto S; Mashima H
Biologics; 2018; 12():69-73. PubMed ID: 30050284
[TBL] [Abstract][Full Text] [Related]
12. Tumor necrosis factor-alpha inhibitor-induced psoriasis or psoriasiform exanthemata: first 120 cases from the literature including a series of six new patients.
Wollina U; Hansel G; Koch A; Schönlebe J; Köstler E; Haroske G
Am J Clin Dermatol; 2008; 9(1):1-14. PubMed ID: 18092839
[TBL] [Abstract][Full Text] [Related]
13. Ustekinumab treatment of TNF antagonist-induced paradoxical psoriasis flare in a patient with psoriatic arthritis: case report and review.
Puig L; Morales-Múnera CE; López-Ferrer A; Geli C
Dermatology; 2012; 225(1):14-7. PubMed ID: 22890275
[TBL] [Abstract][Full Text] [Related]
14. Pustular Psoriasis: A Narrative Review of Recent Developments in Pathophysiology and Therapeutic Options.
Menter A; Van Voorhees AS; Hsu S
Dermatol Ther (Heidelb); 2021 Dec; 11(6):1917-1929. PubMed ID: 34626330
[TBL] [Abstract][Full Text] [Related]
15. [Ustekinumab in a patient with Crohn's disease and anti-TNF-α-induced psoriasis].
Sansó Sureda A; Rocamora Durán V; Sapiña Camaró A; Royo Escosa V; Bosque López MJ
Gastroenterol Hepatol; 2011 Oct; 34(8):546-50. PubMed ID: 21665330
[TBL] [Abstract][Full Text] [Related]
16. Tumor Necrosis Factor Inhibitor-Induced Psoriasis in a Pediatric Crohn's Disease Patient Successfully Treated with Ustekinumab.
Bonomo L; de Moll EH; Li L; Geller L; Gordon MI; Dunkin D
J Drugs Dermatol; 2020 Mar; 19(3):328-331. PubMed ID: 32550694
[TBL] [Abstract][Full Text] [Related]
17.
Borrás-Blasco J; Cortes X; Fernandez-Martinez S; Casterá E; Antequera B
Am J Health Syst Pharm; 2017 Feb; 74(4):209-212. PubMed ID: 28179246
[TBL] [Abstract][Full Text] [Related]
18. Psoriasis induced by infliximab in a patient suffering from Crohn's disease.
Manni E; Barachini P
Int J Immunopathol Pharmacol; 2009; 22(3):841-4. PubMed ID: 19822070
[TBL] [Abstract][Full Text] [Related]
19. Occurrence of plantar pustular psoriasis during treatment with infliximab.
English PL; Vender R
J Cutan Med Surg; 2009; 13(1):40-2. PubMed ID: 19298770
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of ustekinumab in refractory palmoplantar pustular psoriasis.
Morales-Múnera C; Vilarrasa E; Puig L
Br J Dermatol; 2013 Apr; 168(4):820-4. PubMed ID: 23210683
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
